<DOC>
	<DOCNO>NCT01243632</DOCNO>
	<brief_summary>Combination gemcitabine-cisplatin one effective chemotherapy treatment mesothelioma patient . However , median survival patient group 12 month . With intent find effective treatment investigator perform phase II study gemcitabine low dose ( 130-250 mg/m2 ) 6-hours ( prolong ) infusion combination cisplatin advance non-small cell lung cancer ( Zwitter et al . Anticancer Drugs 2005 ; 16:1129-34 ) . After favourable experience , investigator decide explore regiment patient malignant pleural mesothelioma ( MPM ) well .</brief_summary>
	<brief_title>Gemcitabine Long Infusion Cisplatin Malignant Pleural Mesothelioma Treatment</brief_title>
	<detailed_description>The purpose study evaluate new regimen treatment activity malignant pleural mesothelioma ( MPM ) . The primary objective trial assess treatment toxicity , response rate , progress free survival ; secondary objective assessment overall survival quality life . Inclusion criterion : - Biopsy-proven diagnosis MPM - Inoperable anatomic physiological reason - Measurable previously unirradiated lesion - Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 - 2 - Adequate haematopoietic , liver , kidney function . - Signed informed consent participation trial Exclusion criterion : - Significant medical co-morbidity - Pregnant lactate woman - History cancer previous 10 year breast cancer ever . The general treatment schedule identical patient : gemcitabine 6-hours infusion day 1 8 , cisplatin 75 mg/m2 day 2 3-weekly cycle standard antiemetic treatment use metoclopramide , dexamethasone , aprepitant , granisetron . After 4 cycle , patient progression without serious toxicity continue additional 2 cycle monotherapy gemcitabine prolonged infusion . National Cancer Institute Common Toxicity Criteria ( NCI CTC ) , version 2.0 use grade toxicity . In day administration cytotoxic drug complete blood cell count chemistry panel perform , treatment reduce avoided event bone marrow suppression decline renal clearance . In case Grade I ( NCI CTC , vs. 2.0 ) neutropenia and/or thrombocytopenia , dose gemcitabine reduce 75 % ; drug omit Grade II great neutro/thrombocytopenia . Cisplatin omit case Grade â‰¥ II nephrotoxicity and/or grade III nausea vomiting .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Biopsyproven diagnosis malignant pleural mesothelioma Inoperable anatomic physiological reason Measurable previously unirradiated lesion Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 Adequate haematopoietic , liver , kidney function . Signed informed consent participation trial Significant medical comorbidity Pregnant lactate woman History cancer previous 10 year breast cancer ever .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>malignant pleural mesothelioma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>long infusion</keyword>
</DOC>